Harwood Feffer LLP Announces Investigation of Ambit Biosciences Corporation

NEW YORK, Sept. 29, 2014 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Ambit Biosciences Corporation ("Ambit" or the "Company") (NASDAQ: AMBI) concerning the proposed acquisition of the Company by Daiichi Sankyo Co. ("Daiichi Sankyo").    

Under the terms of the transaction, Daiichi Sankyo would acquire Ambit in a transaction valued at approximately $410 million.  Ambit shareholders are being offered $15.00 in cash plus the right to receive a payment of as much as $4.50 per share if certain milestones are achieved.    

Our investigation concerns whether the Ambit board of directors is fulfilling its fiduciary duties, maximizing the value of the Company, disclosing all material benefits and costs, and obtaining full and fair consideration for Company stockholders. 

If you own Ambit shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:

Benjamin I. Sachs-Michaels, Esq.
Robert I. Harwood, Esq.
Craig Lowther
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212)935-7400
Email: bsachsmichaels@hfesq.com
Website: http://www.hfesq.com 
Follow us on Twitter: @HarwoodFeffer

Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.

Attorney Advertising. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Logo - http://photos.prnewswire.com/prnh/20120215/MM54604LOGO

SOURCE Harwood Feffer LLP